School of Medicine, University of California San Francisco, San Francisco, California.
Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Francisco, San Francisco, California.
Kidney360. 2021 Mar 3;2(5):819-827. doi: 10.34067/KID.0005182020. eCollection 2021 May 27.
Kidney replacement therapy is controversial for patients with hepatorenal syndrome who may not be liver transplant candidates. Data surrounding the likelihood of recovery of kidney function and mortality after outpatient dialysis initiation in patients with dialysis-requiring hepatorenal syndrome could inform discussions between patients and providers.
We performed a retrospective cohort study of patients with hepatorenal syndrome who were registered in the United States Renal Data System between 1996 and 2015 (=7830) as receiving maintenance dialysis. We characterized patients with hepatorenal syndrome by recovery of kidney function using Fine and Gray models. We also examined hazard of recovery of kidney function and death among those with hepatorenal syndrome versus those with acute tubular necrosis (=48,861) using adjusted Fine-Gray and Cox models, respectively.
Of the patients with hepatorenal syndrome, 11% recovered kidney function. Those with higher likelihood of recovery were younger, non-Hispanic White, and had a history of alcohol use. Compared with patients with acute tubular necrosis, patients with hepatorenal syndrome as the attributed cause of kidney disease had a lower hazard of recovery (HR, 0.22; 95% CI, 0.21 to 0.24) and higher hazard of death within 1 year (HR, 3.10; 95% CI, 2.99 to 3.23) in fully adjusted models.
Patients with hepatorenal syndrome receiving chronic maintenance dialysis had a lower likelihood of recovery of kidney function and higher mortality risk compared with patients with acute tubular necrosis. Among patients with hepatorenal syndrome, those most likely to recover kidney function were younger, had a history of alcohol use, and lacked comorbid conditions. These data may inform prognosis and discussions surrounding treatment options when patients with hepatorenal syndrome need chronic maintenance dialysis therapy.
对于可能不是肝移植候选者的肝肾综合征患者,肾脏替代疗法存在争议。在门诊透析开始后,有透析需求的肝肾综合征患者肾功能恢复和死亡率的数据可以为患者和医生之间的讨论提供信息。
我们对 1996 年至 2015 年期间在美国肾脏数据系统登记的需要维持透析的肝肾综合征患者进行了回顾性队列研究(=7830)。我们使用 Fine 和 Gray 模型来描述肝肾综合征患者的肾功能恢复情况。我们还使用调整后的 Fine-Gray 和 Cox 模型分别检查了肝肾综合征患者与急性肾小管坏死患者(=48861)肾功能恢复和死亡的风险。
在肝肾综合征患者中,11%的患者恢复了肾功能。那些更有可能恢复肾功能的患者年龄较小,是非西班牙裔白人,并且有饮酒史。与急性肾小管坏死患者相比,作为肾脏疾病归因原因的肝肾综合征患者肾功能恢复的风险较低(HR,0.22;95%CI,0.21 至 0.24),并且在完全调整的模型中,1 年内死亡的风险较高(HR,3.10;95%CI,2.99 至 3.23)。
接受慢性维持性透析的肝肾综合征患者肾功能恢复的可能性较低,死亡率较高。在肝肾综合征患者中,最有可能恢复肾功能的患者是年龄较小、有饮酒史且没有合并症的患者。这些数据可能会告知预后,并在需要慢性维持性透析治疗的肝肾综合征患者的治疗方案讨论中提供信息。